Medicines

Sun Pharma launches blockbuster plaque psoriasis drug Ilumya in India

Ilumya, a novel biologic treatment that selectively inhibits IL-23, has already established itself as a blockbuster drug internationally, with presence across 35 countries

As anti-vaccine conferences rise, future of medicine seems to be in trouble

Vaccine decisions today go beyond personal risk-benefit - they carry cultural and political weight, often leading to judgement when outcomes don't go as expected

Sun Pharma Q2 net profit rises 2.5% to ₹3,118 crore on India, EM growth

Sun Pharma's Q2FY26 profit rose to Rs 3,118 crore as India, emerging markets, and rest of world drove growth; US revenues fell 4.1% despite strong gains in innovative medicines

Cough syrup deaths: NHRC sends notices to MP, Rajasthan, Uttar Pradesh

NHRC issues notices to MP, Rajasthan and UP, asks states to probe children's deaths from alleged use of contaminated cough syrups

From silica gel to smart sorbents: How pharma packaging is evolving

Loose silica gel packets are being replaced by built-in smart sorbents that block moisture, oxygen, and odour, boosting safety, stability and patient convenience

Know your risk: How to stay safe from serious medicine side-effects

From skin rashes to seizures, here's how to spot adverse drug reactions early and protect yourself with timely medical action

Is it safe to mix Ayurveda with modern medicine? Here's what doctors say

Mixing Ayurvedic remedies with prescription drugs may seem harmless, but it can cause serious side effects or reduce treatment efficacy unless done under medical guidance

No need to relabel existing medicine stock: FinMin on new GST rates

Finance Ministry clarified that medicines released before Sept 22 need not be recalled or relabelled under GST 2.0, with compliance ensured via revised price lists at retail level

Anti-obesity diabetes drugs receive WHO's essential medicine tag

WHO adds GLP-1 drugs for type 2 diabetes to its Essential Medicines List, as Indian pharma firms prepare to launch generics amid surging demand and patent expirations

CDSCO flags 4 drugs as spurious, 185 not of standard quality for June 2025

CDSCO has flagged four drugs as spurious and 185 others as not of standard quality for June 2025. The list includes antibiotics and heart disease medications. Investigations are underway

'AFMS looking at drone use to supply blood bags, medicines in hilly areas'

The Armed Forces Medical Services is exploring the use of drone technology to deliver blood bags, medicines and other medical supplies in hilly and hard-to-reach areas, Director General of AFMS, Surgeon Vice Admiral Arti Sarin, has said. She also said the AFMS was responsible for the health requirements of all four astronauts currently part of the Axiom-4 mission to the International Space Station. Vice Admiral Sarin was speaking on Saturday on the sidelines of a commissioning ceremony for five medical cadets at the Armed Forces Medical College (AFMC) in Pune. She said the AFMS is integrating modern technologies like telemedicine, Artificial Intelligence (AI), point-of-care devices, and drones to strengthen healthcare delivery. We are looking at using drone technology for the supply of blood bags, medicines, and other medical equipment. In fact, we are hoping for a day when even medical evacuations can be carried out using drones, she said. The technology is currently being consid

Drugmakers may lose product licence if govt labs flag quality failures

The Health Ministry is working with states to allow immediate suspension of licences for drugs declared substandard by labs, following a key recommendation from Drugs Technical Advisory Board

Kashmik Formulation targets ₹100 crore revenue in FY26, eyes IPO

The company currently produces around 25 crore units a month and is expanding its ground and first-floor production facilities to meet rising demand

US FDA to fast-track drug reviews for firms backing national priorities

US regulators will begin offering faster reviews to new medicines that administration officials deem as promoting the health interests of Americans, under a new initiative announced Tuesday. Food and Drug Administration Commissioner Marty Makary said the agency will aim to review select drugs in one to two months. FDA's long-standing accelerated approval program generally issues decisions in six months for drugs that treat life-threatening diseases. Regular drug reviews take about 10 months. Since arriving at the FDA in April, Makary has repeatedly told FDA staff they need to challenge assumptions and rethink procedures. In a medical journal commentary published last week, Makary suggested the agency could conduct rapid or instant reviews," pointing to the truncated process used to authorize the first COVID-19 vaccines under Operation Warp Speed. For the new program, the FDA will issue a limited number of national priority vouchers to companies aligned with U.S. national priorities,

Anti-infective drug sales surge in May as fever season grips country

Analysts indicate sales in the segment are expected to grow more during monsoon months

Study finds key drug shortages for diabetes, BP at rural health centres

A joint survey conducted by the ICMR and the WHO, along with other institutes, has revealed critical medicine shortages for managing diabetes and hypertension at rural health facilities, from sub-centres to sub-district hospitals, across 19 districts in seven states. The study has also found a shortage of specialists at the community health centre (CHC) level and these findings are similar to the rural health statistics report of 2020-21, indicating a shortfall of physicians (82.2 per cent) and surgeons (83.2.9 per cent) at the CHC-level. The study findings, published in the "Indian Journal of Medical Research (IJMR)" suggest that among public health facilities, PHCs, district hospitals and government medical colleges in India are better prepared to manage services for diabetes and hypertension. Across all the facilities, the domain score for equipment was the highest and for medicines, it was the lowest. However, the availability of all medicines was better at tertiary-care ...

Eli Lilly's tirzepatide shows superior weight loss to Novo's semaglutide

Phase 3b trial finds Lilly's tirzepatide delivers higher average weight loss and waist reduction than Novo's semaglutide in people with obesity or overweight

Donald Trump seeks to align US drug costs with cheapest ones abroad

The US government already negotiates prices for some of the highest-cost medicines used in Medicare health insurance under the Inflation Reduction Act

Doctors must prescribe only generic drugs, not branded medicines: SC

The Supreme Court has said doctors should prescribe only generic drugs. The court made the remark while hearing a PIL seeking tighter regulation of pharmaceutical marketing practices

Booster dose: India inches closer to regulatory framework for OTC drugs

DTAB has accepted sub-panel recommendation on OTC drugs list